Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

AMRI Global

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. The company provides scientific services, products and technologies that improve quality of life while delivering excellence, value and maximum return.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Genesis Research Group logo

Genesis Research Group

Genesis Research Group empowers life science companies to innovate differently by fundamentally transforming the way they engage with research partners. Through the integration of robust stakeholder insights (RPR), data-agnostic expertise,…

View Profile

Market access, Regulatory affairs, Research and development

Company Details

AMRI Global
Mostyn Road, Holywell, Flintshire, Wales, CH8 9DN, United Kingdom
+44 (0)1352 717100
Contact AMRI Global
Website

 Latest Content from PMHub 

It’s a Medscape wrap for EHA2022

Press Releases | June 21, 2022 | Medscape Education

EHA2022 Hybrid Congress has now come to a close with the Thematic Days finishing last week. The Medscape team were delighted to connect with so many physicians, colleagues and supporters...

EVOKE MIND+MATTER BROADENS STRATEGIC CAPABILITY WITH FULL-SERVICE RESEARCH & INSIGHTS OFFERING

Press Releases | June 17, 2022 | Inizio

Headed up by Research Director, Angela McMean, the Evoke Mind+Matter Insights division comprises a team of primary research specialists focused on delivering meaningful, data-driven insight that supports the agency’s mission...

Amplifying Opinions of Patients & Caregivers for Higher Quality of Care

Videos and Podcasts | June 16, 2022 | Impetus Digital

Pam Cusick, Senior Vice President of Rare Patient Voice, dives into diversity, equity, and inclusion in Pharma and clinical trials; ways to enhance the patient’s voice in their treatment journey...

Data-driven policy and market access firm Avalere joins Fishawack Health

Press Releases | June 16, 2022 | Avalere Health

Fishawack Health bolsters its commercialization service offering with its largest addition to date, welcoming US-based policy, market access, and transformation leader Avalere.

Cuttsy+Cuttsy gain highly regarded PIF Partner status

Press Releases | June 16, 2022 | Cuttsy + Cuttsy

As official PIF Partners, Cuttsy+Cuttsy will be supporting the Patient Information Forum raise awareness of the PIF TICK.

Science for science sake

White Papers and Resources | June 16, 2022 | Dice Medical Communications

Like great works of art, there was no ‘reason’ for certain scientific endeavours, but this ‘just for the sake of it’ philosophy is now delivering tangible benefits. (article written 3rd...

Embrace mental health first aiders for better work wellbeing

White Papers and Resources | June 15, 2022 | Page & Page Health

Mental health first aid can work as a vital steppingstone to instilling good mental health practices into wider company culture and ensure everyone knows what to be looking out for...

Celebrating World Blood Donor Day

White Papers and Resources | June 15, 2022 | Innovative Trials

Each 14th June World Blood Donor day is celebrated around the world to spread awareness around the importance of giving blood.

Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed

Press Releases | June 13, 2022 | Wilmington Healthcare

Wilmington Healthcare’s State of the Nation prescribing report shows that spending on sertraline, commonly used to treat depression and anxiety, increased by 305.5% between 2019/20 and 2020/21 while overall spend...

Accelerating patient recruitment in clinical trials post COVID-19

Videos and Podcasts | June 13, 2022 | Innovative Trials

Patient recruitment is arguably one of the most important aspects of a clinical trial. Without enough participants, trials will inevitably fail, meaning potentially effective therapies will not be brought to...